Biotech · Private company · Bronx, NY, US
Oligomerix, Inc
Track this companyFree. Adds Oligomerix, Inc to your Dealase workspace and tells you when its record changes.
Clinical trials11 recruiting or active
Pipeline programs1From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline1
- OLX-07010 ActivePhase 1 · Alzheimer DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials1
- Phase 1 Study of OLX-07010 in Healthy Adult and Elderly ParticipantsPHASE1 · ACTIVE_NOT_RECRUITING · started Jan 20, 2023ClinicalTrials.gov NCT05696483 · fetched Nov 12, 2026
NIH awards4
- A 13-Week Oral Gavage Toxicity Study of OLX-07010 in Beagle Dogs Followed by a 4-Week Recovery PeriodFiscal year 2026 · $1.5MNIH RePORTER 4R44AG091987-02 · fetched Nov 12, 2026
- A 13-Week Oral Gavage Toxicity Study of OLX-07010 in Beagle Dogs Followed by a 4-Week Recovery PeriodFiscal year 2025 · $499.9KNIH RePORTER 1R44AG091987-01 · fetched Nov 12, 2026
- First in Human Study of a Tau Self-Association Small Molecule Inhibitor in Healthy VolunteersFiscal year 2024 · $336.9KNIH RePORTER 3R01AG076565-02S1 · fetched Nov 12, 2026
- GMP Production of a Tau Oligomer Inhibitor to Enable Clinical Development forADRDFiscal year 2024 · $1.5MNIH RePORTER 5R44AG066384-04 · fetched Nov 12, 2026